Abstract
Aim To perform the first national analysis of demographic and clinicopathological features associated with the HER2 positive, HER2-low and HER2-zero invasive breast cancers in New Zealand. The study will inform the proportion of women who benefit from new HER2-targeted antibody drug conjugate (ADC) therapies.
Methods Utilising data from Te Rēhita Mate Ūtaetae (Breast Cancer Foundation NZ National Register), the study analysed data from women diagnosed with invasive breast cancer over a 21-year period. The HER2 status of tumours was classified into three categories – HER2-zero, -low, - positive.
Results From 2009-2021, 94% of women underwent HER2 testing, with 14% diagnosed with HER2-positive breast cancer. For advanced-stage disease, 38% formerly classified as HER2-negative were reclassified as HER2-low. Including HER2-positive breast cancers, this indicates 60% of women with advanced breast cancer would be eligible for the new HER2-directed ADCs (approximately 120 women per year). In future, these therapies may provide a targeted option for 40% of women with early-stage triple negative breast cancer now classified as HER2-low.
Conclusion The findings suggest a significant proportion of women with invasive breast cancer in New Zealand could benefit from new HER2-targeted treatments. There is a need to standardise HER2 testing to enhance personalised treatment and improve outcomes.
Competing Interest Statement
This study was funded by a grant from AstraZeneca. However, AstraZeneca had no role in the study design, data collection, data analysis, interpretation of the data, or in the writing of this manuscript.
Funding Statement
This study was funded by a grant from AstraZeneca.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the University of Auckland game ethical approval for this work via the the Auckland Health Research Ethics Committee (AH2800).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to Te Rēhita Mate Ūtaetae.
